

Status of Claims:

---

1-15 (Cancelled herein)

16-26 (previously cancelled)

27-32 (Cancelled herein)

~~33.~~ (New) A formulation for rectal administration by enema comprising an antisense oligonucleotide, said antisense oligonucleotide comprising (SEQ. ID NO:1).

34. (New) A formulation according to claim 33 further comprising at least one penetration enhancer.

35. (New) A formulation according to claim 34 wherein said penetration enhancer is a fatty acid, bile salt, chelating agent, surfactant or non-chelating non-surfactant.

C' 36. (New) A formulation according to claim 33 wherein said formulation comprises an emulsion.

37. (New) A formulation according to claim 33 wherein said formulation comprises a solution.

38. (New) A formulation according to claim 36 further comprising at least one penetration enhancer.

39. (New) A formulation according to claim 37 further comprising at least one penetration enhancer.